Arrhythmic risk stratification in ischemic, non-ischemic and hypertrophic cardiomyopathy: A two-step multifactorial, electrophysiology study inclusive approach

Table 2 Prevalence of non-invasive risk factors in the total sample, in the truly high-risk group, detected after the two-step, electrophysiology inclusive approach, and in patients with major arrhythmic events during a 32-mo follow-up, as investigated in the PRESERVE EF study[24]

NIRF	Prevalence in the total preserve-EF study (n = 577)	Prevalence in the high-risk group (n = 41)	Prevalence in 9 MAE/SCD patients
LPs (%)	13.8	51.2	78 (7/9)
NSVT (%)	8.6	46.3	66 (6/9)
QTc (%)	13.6	36.6	55 (5/9)
VPBs (%)	10.8	39	33 (3/9)
TWA (%)	6.8	24.4	11 (1/9)
SDNN (%)	2.8	9.8	0 (0/9)
HRT and DC (%)	2.8	9.8	0 (0/9)

DC: Deceleration capacity from heart rate dynamics; HRT: Heart rate turbulence from heart rate dynamics; LPs: Late potentials from signal-averaged electrocardiogram; MAE: Major arrhythmic event; NIRF: Non-invasive risk factor; NSVT: Non-sustained ventricular tachycardia; QTc: Corrected according to Fridericia formula QT interval; SDNN: Standard deviation of normal to normal beats from heart rate variability analysis; TWA: T wave alternans; VPBs: Ventricular premature beats.